Edition:
United Kingdom

Zynerba Pharmaceuticals Inc (ZYNE.OQ)

ZYNE.OQ on NASDAQ Stock Exchange Global Market

6.28USD
17 Aug 2018
Change (% chg)

$-0.29 (-4.41%)
Prev Close
$6.57
Open
$6.50
Day's High
$6.56
Day's Low
$6.26
Volume
59,786
Avg. Vol
99,495
52-wk High
$15.12
52-wk Low
$5.59

Chart for

About

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which... (more)

Overall

Beta: --
Market Cap(Mil.): $128.07
Shares Outstanding(Mil.): 13.26
Dividend: --
Yield (%): --

Financials

  ZYNE.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -2.62 -- --
ROI: -55.80 1.78 14.61
ROE: -55.80 3.28 16.33

BRIEF-Zynerba Pharmaceuticals Reports Q1 Loss Of $0.91 Per Share

* ZYNERBA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

08 May 2018

BRIEF-Zynerba Pharmaceuticals Says ZYN002 Was Shown To Be Well Tolerated Through 12 Months Of Treatment In Star 2 Study

* ZYNERBA PHARMACEUTICALS SAYS ZYN002 WAS SHOWN TO BE WELL TOLERATED THROUGH 12 MONTHS OF TREATMENT IN STAR 2

25 Apr 2018

BRIEF-Zynerba Pharmaceuticals Appoints John P. Butler To Board Of Directors

* ZYNERBA PHARMACEUTICALS APPOINTS JOHN P. BUTLER TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

16 Apr 2018

BRIEF-Zynerba Pharmaceuticals Initiates Open Label Phase 2 Trial Of ZYN002 In Developmental And Epileptic Encephalopathies (DEE)

* ZYNERBA PHARMACEUTICALS INITIATES OPEN-LABEL PHASE 2 TRIAL OF ZYN002 IN DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES (DEE)

10 Apr 2018

BRIEF-Zynerba Pharmaceuticals Reports Q4 Loss Per Share $0.60

* ZYNERBA PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

12 Mar 2018

BRIEF-Zynerba Pharma Plans To Conduct Single Pivotal Study Of ZYN002 In Fragile X Syndrome To Support NDA Filing

* ZYNERBA PHARMACEUTICALS ANNOUNCES POSITIVE MEETING WITH U.S. FOOD AND DRUG ADMINISTRATION AND PLANS TO CONDUCT A SINGLE PIVOTAL STUDY OF ZYN002 IN FRAGILE X SYNDROME TO SUPPORT AN NDA FILING

05 Mar 2018

Earnings vs. Estimates